Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oyster Point Pharma, Inc.OYST · Entity 15903 | Director | June 08, 2020 | June 10, 2020 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director | June 16, 2022 | July 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oyster Point Pharma, Inc.
Report date June 08, 2020 · Filed June 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 152,162 |
Reported balance
After 2020-06-08 transaction · row 1
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 14,805 · Balance 152,162 F1: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2: The shares underlying the RSU vest as to one-twelfth (1/12th) of the RSU on July 8, 2020 and monthly thereafter on the same day of the month as the grant date; however, the shares underlying the RSU will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 140,567 |
Reported balance
Holding disclosure · report date 2020-06-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 140,567 F3: These shares are held through a trust, the sole trustee of which is the Reporting Person and the beneficiaries of which are immediate family members of the Reporting Person, including the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F2: The shares underlying the RSU vest as to one-twelfth (1/12th) of the RSU on July 8, 2020 and monthly thereafter on the same day of the month as the grant date; however, the shares underlying the RSU will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date.
F3: These shares are held through a trust, the sole trustee of which is the Reporting Person and the beneficiaries of which are immediate family members of the Reporting Person, including the Reporting Person.
Tarsus Pharmaceuticals, Inc.
Report date June 16, 2022 · Filed July 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2032-06-15 | Direct | 7,000 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 7,000 · Balance 7,000 F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,000 |
Reported balance
After 2022-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-16 · Grant · Acquired 12,000 · Balance 12,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2022 Filed Jul 1, 2022 16:31 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-018349 · wf-form4_165669310580119.xml · derivative · entry 2 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 16, 2022 Filed Jul 1, 2022 16:31 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001628280-22-018349 · wf-form4_165669310580119.xml · derivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037924 · doc4.xml · derivative · entry 3 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted on June 15, 2021 in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F4 · derivative.expiration_date: RSUs granted on June 15, 2021 in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 4,257 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-037924 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| May 05, 2022 Filed May 9, 2022 20:42 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | PurchaseCommon Stock | 100,000 | $13.50 | $1,350,000.00 |
DisclosureSEC source: 0001209191-22-027856 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Ackermann & Elmen-Gruys Trust Dated June 24, 2014 Disclosed balance after: 100,000 F1 · shares: The Reporting Person purchased the shares of common stock reported hereby from the underwriters in an underwritten public offering conducted by the Issuer pursuant to an underwriting agreement, dated May 2, 2022, between the Issuer and the representatives of the several underwriters. Each share of common stock was sold by the underwriters at a price of $13.50 per share. F2 · ownership.nature: The Reporting Person is the trustee of the Ackermann & Elmen-Gruys Trust Dated June 24, 2014 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 528 | $26.65 | $14,071.20 |
DisclosureSEC source: 0001819790-21-000059 · wf-form4_163857580594057.xml · nonDerivative · entry 4 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,204,016 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F5 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.53 to $27.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 809 | $25.87 | $20,928.83 |
DisclosureSEC source: 0001819790-21-000059 · wf-form4_163857580594057.xml · nonDerivative · entry 3 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,204,544 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.51 to $26.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,054 | $24.68 | $50,692.72 |
DisclosureSEC source: 0001819790-21-000059 · wf-form4_163857580594057.xml · nonDerivative · entry 2 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,205,353 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $24.28 to $25.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,442 | $23.85 | $58,241.70 |
DisclosureSEC source: 0001819790-21-000059 · wf-form4_163857580594057.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,207,407 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $23.24 to $24.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:00 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 869 | $28.18 | $24,488.42 |
DisclosureSEC source: 0001819790-21-000043 · wf-form4_163598040275686.xml · nonDerivative · entry 2 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,209,849 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $28.11 to $28.27. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:00 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,964 | $27.76 | $137,800.64 |
DisclosureSEC source: 0001819790-21-000043 · wf-form4_163598040275686.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210,718 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $27.10 to $28.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 20:48 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,517 | $26.45 | $119,474.65 |
DisclosureSEC source: 0001819790-21-000039 · wf-form4_163424449168205.xml · nonDerivative · entry 2 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,682 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.12 to $26.93. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 20:48 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,116 | $25.56 | $28,524.96 |
DisclosureSEC source: 0001819790-21-000039 · wf-form4_163424449168205.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,199 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.08 to $26.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 22:47 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 200 | $25.03 | $5,006.00 |
DisclosureSEC source: 0001819790-21-000035 · wf-form4_163407884464685.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,221,315 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.000 to $25.06, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,833 | $25.24 | $147,236.59 |
DisclosureSEC source: 0001209191-21-054888 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,221,515 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.000 to $25.970, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 21:27 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 621 | $25.15 | $15,619.39 |
DisclosureSEC source: 0001209191-21-051193 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227,348 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.030 to $25.250, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 700 | $25.00 | $17,500.00 |
DisclosureSEC source: 0001209191-21-050631 · doc4.xml · nonDerivative · entry 2 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227,969 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,129 | $25.00 | $78,225.00 |
DisclosureSEC source: 0001209191-21-050631 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,228,669 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:16 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 100 | $25.01 | $2,501.00 |
DisclosureSEC source: 0001209191-21-050177 · doc4.xml · nonDerivative · entry 3 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,798 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:16 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 100 | $25.01 | $2,500.50 |
DisclosureSEC source: 0001209191-21-050177 · doc4.xml · nonDerivative · entry 2 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,898 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:16 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,183 | $25.00 | $29,575.00 |
DisclosureSEC source: 0001209191-21-050177 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,998 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 4,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041701 · doc4.xml · derivative · entry 4 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,257 Underlying: Common Stock · 4,257 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F5 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $35.26 | $0.00 |
DisclosureSEC source: 0001209191-21-041701 · doc4.xml · derivative · entry 3 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-15 F3 · derivative.exercise_date: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $35.26 | $0.00 |
DisclosureSEC source: 0001209191-21-041701 · doc4.xml · derivative · entry 2 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-15 F2 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantCommon Stock | 4,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041701 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233,181 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The RSUs are fully vested as of the date of grant. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:54 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries B Preferred Stock · Derivative | 9,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055420 · doc4.xml · derivative · entry 4 Ackermann Michael · CIK 0001791249 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,246 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:54 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries A Preferred Stock · Derivative | 53,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055420 · doc4.xml · derivative · entry 3 Ackermann Michael · CIK 0001791249 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,939 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:54 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 9,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055420 · doc4.xml · nonDerivative · entry 2 Ackermann Michael · CIK 0001791249 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,228,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:54 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 53,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055420 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:12 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | GrantCommon Stock | 14,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035746 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,162 F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: The shares underlying the RSU vest as to one-twelfth (1/12th) of the RSU on July 8, 2020 and monthly thereafter on the same day of the month as the grant date; however, the shares underlying the RSU will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 17:47 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionSeries A Convertible Preferred Stock · Derivative | 140,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026590 · doc4.xml · derivative · entry 2 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 140,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date. F1 · price: These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Held through a trust, the sole trustee of which is the Reporting Person and the sole beneficiaries of which are immediate family members of the Reporting Person, including the Reporting Person. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 17:47 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionCommon Stock, par value $0.001 per share | 140,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026590 · doc4.xml · nonDerivative · entry 1 Ackermann Michael · CIK 0001791249 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 140,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Held through a trust, the sole trustee of which is the Reporting Person and the sole beneficiaries of which are immediate family members of the Reporting Person, including the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.